Current Recommendations and Novel Strategies for the Management of Skin Toxicities Related to Anti-EGFR Therapies in Patients with Metastatic Colorectal Cancer
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Current Recommendations and Novel Strategies for the Management of Skin Toxicities Related to Anti-EGFR Therapies in Patients with Metastatic Colorectal Cancer
Authors
Keywords
-
Journal
CLINICAL DRUG INVESTIGATION
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2019-07-01
DOI
10.1007/s40261-019-00811-7
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Dermatologic Toxicity Occurring During Anti-EGFR Monoclonal Inhibitor Therapy in Patients With Metastatic Colorectal Cancer: A Systematic Review
- (2018) Mario E. Lacouture et al. Clinical Colorectal Cancer
- Management and grading of EGFR inhibitor-induced cutaneous toxicity
- (2018) Janette Beech et al. Future Oncology
- Targeted therapies and adverse drug reactions in oncology: the role of clinical pharmacist in pharmacovigilance
- (2018) G. Fornasier et al. International Journal of Clinical Pharmacy
- NCCN Task Force Report: Management of Dermatologic and Other Toxicities Associated With EGFR Inhibition in Patients With Cancer
- (2017) Barbara Burtness et al. Journal of the National Comprehensive Cancer Network
- ESMO consensus guidelines for the management of patients with metastatic colorectal cancer
- (2016) E. Van Cutsem et al. ANNALS OF ONCOLOGY
- Antibiotic prophylaxis for skin toxicity induced by antiepidermal growth factor receptor agents: a systematic review and meta-analysis
- (2016) F. Petrelli et al. BRITISH JOURNAL OF DERMATOLOGY
- Skin problems and EGFR-tyrosine kinase inhibitor
- (2016) Toshiyuki Kozuki JAPANESE JOURNAL OF CLINICAL ONCOLOGY
- Recommendations for the Prophylactic Management of Skin Reactions Induced by Epidermal Growth Factor Receptor Inhibitors in Patients With Solid Tumors
- (2016) R.-D. Hofheinz et al. ONCOLOGIST
- Skin toxicity and quality of life during treatment with panitumumab for RAS wild-type metastatic colorectal carcinoma: results from three randomised clinical trials
- (2016) Reija Koukakis et al. QUALITY OF LIFE RESEARCH
- EGFR inhibitor-induced skin reactions: differentiating acneiform rash from superimposed bacterial infections
- (2016) Rachel L. Braden et al. SUPPORTIVE CARE IN CANCER
- Late epidermal growth factor receptor inhibitor-related papulopustular rash: a distinct clinical entity
- (2015) V. Sibaud et al. CLINICAL AND EXPERIMENTAL DERMATOLOGY
- Randomized controlled trial on the skin toxicity of panitumumab in Japanese patients with metastatic colorectal cancer: HGCSG1001 study; J-STEPP
- (2015) Yoshimitsu Kobayashi et al. Future Oncology
- Metastatic Colorectal Cancer: Current State and Future Directions
- (2015) Marwan G. Fakih JOURNAL OF CLINICAL ONCOLOGY
- Fluorouracil, Leucovorin, and Irinotecan Plus Cetuximab Treatment andRASMutations in Colorectal Cancer
- (2015) Eric Van Cutsem et al. JOURNAL OF CLINICAL ONCOLOGY
- Impact of Dermatologic Adverse Events on Quality of Life in 283 Cancer Patients: A Questionnaire Study in a Dermatology Referral Clinic
- (2013) Alyx C. Rosen et al. AMERICAN JOURNAL OF CLINICAL DERMATOLOGY
- Panitumumab–FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer
- (2013) Jean-Yves Douillard et al. NEW ENGLAND JOURNAL OF MEDICINE
- A review of the treatment options for skin rash induced by EGFR-targeted therapies: Evidence from randomized clinical trials and a metaanalysis
- (2013) Janja Ocvirk et al. Radiology and Oncology
- Epidermal EGFR Controls Cutaneous Host Defense and Prevents Inflammation
- (2013) B. M. Lichtenberger et al. Science Translational Medicine
- Quality of life analysis in patients with KRAS wild-type metastatic colorectal cancer treated first-line with cetuximab plus irinotecan, fluorouracil and leucovorin
- (2012) István Láng et al. EUROPEAN JOURNAL OF CANCER
- Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study
- (2011) C. Bokemeyer et al. ANNALS OF ONCOLOGY
- Rash rates with EGFR inhibitors: meta-analysis
- (2011) N. Mittmann et al. Current Oncology
- Management of Skin Toxicity Associated with Cetuximab Treatment in Combination with Chemotherapy or Radiotherapy
- (2011) C. Pinto et al. ONCOLOGIST
- Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities
- (2011) Mario E. Lacouture et al. SUPPORTIVE CARE IN CANCER
- Effects of epidermal growth factor receptor inhibitor-induced dermatologic toxicities on quality of life
- (2010) Smita S. Joshi et al. CANCER
- Randomized Phase III Study of Panitumumab With Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) Compared With FOLFIRI Alone As Second-Line Treatment in Patients With Metastatic Colorectal Cancer
- (2010) Marc Peeters et al. JOURNAL OF CLINICAL ONCOLOGY
- Skin Toxicity Evaluation Protocol With Panitumumab (STEPP), a Phase II, Open-Label, Randomized Trial Evaluating the Impact of a Pre-Emptive Skin Treatment Regimen on Skin Toxicities and Quality of Life in Patients With Metastatic Colorectal Cancer
- (2010) Mario E. Lacouture et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME Study
- (2010) Jean-Yves Douillard et al. JOURNAL OF CLINICAL ONCOLOGY
- Prophylactic tetracycline does not diminish the severity of epidermal growth factor receptor (EGFR) inhibitor-induced rash: results from the North Central Cancer Treatment Group (Supplementary N03CB)
- (2010) Aminah Jatoi et al. SUPPORTIVE CARE IN CANCER
- Dermatologic Infections in Cancer Patients Treated With Epidermal Growth Factor Receptor Inhibitor Therapy
- (2009) R. E. Eilers et al. JNCI-Journal of the National Cancer Institute
- Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
- (2009) Eric Van Cutsem et al. NEW ENGLAND JOURNAL OF MEDICINE
- Chapter 2. Fusidic acid in skin and soft-tissue infections
- (2008) BH Long ACTA DERMATO-VENEREOLOGICA
- Tetracycline to prevent epidermal growth factor receptor inhibitor-induced skin rashes
- (2008) Aminah Jatoi et al. CANCER
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started